The Experts below are selected from a list of 198 Experts worldwide ranked by ideXlab platform
Robert Wesolowski - One of the best experts on this subject based on the ideXlab platform.
-
incidence of infusion site reactions associated with peripheral Intravenous Administration of fosaprepitant
Supportive Care in Cancer, 2014Co-Authors: Jordan Lundberg, Brooke Sorgen Crawford, Gary Phillips, Michael J. Berger, Robert WesolowskiAbstract:Purpose Fosaprepitant is known to cause infusion-site reactions. However, there is limited data regarding these reactions including the effect of peripheral Intravenous Administration or other potential factors on their incidence. This single-institution retrospective study was undertaken to investigate the incidence of infusion-site reactions with single-dose Intravenous (IV) fosaprepitant when given through a peripheral line prior to Administration of chemotherapy. Risk factors for the development of infusion-site reactions with fosaprepitant were also explored.
Jordan Lundberg - One of the best experts on this subject based on the ideXlab platform.
-
incidence of infusion site reactions associated with peripheral Intravenous Administration of fosaprepitant
Supportive Care in Cancer, 2014Co-Authors: Jordan Lundberg, Brooke Sorgen Crawford, Gary Phillips, Michael J. Berger, Robert WesolowskiAbstract:Purpose Fosaprepitant is known to cause infusion-site reactions. However, there is limited data regarding these reactions including the effect of peripheral Intravenous Administration or other potential factors on their incidence. This single-institution retrospective study was undertaken to investigate the incidence of infusion-site reactions with single-dose Intravenous (IV) fosaprepitant when given through a peripheral line prior to Administration of chemotherapy. Risk factors for the development of infusion-site reactions with fosaprepitant were also explored.
Brooke Sorgen Crawford - One of the best experts on this subject based on the ideXlab platform.
-
incidence of infusion site reactions associated with peripheral Intravenous Administration of fosaprepitant
Supportive Care in Cancer, 2014Co-Authors: Jordan Lundberg, Brooke Sorgen Crawford, Gary Phillips, Michael J. Berger, Robert WesolowskiAbstract:Purpose Fosaprepitant is known to cause infusion-site reactions. However, there is limited data regarding these reactions including the effect of peripheral Intravenous Administration or other potential factors on their incidence. This single-institution retrospective study was undertaken to investigate the incidence of infusion-site reactions with single-dose Intravenous (IV) fosaprepitant when given through a peripheral line prior to Administration of chemotherapy. Risk factors for the development of infusion-site reactions with fosaprepitant were also explored.
Gary Phillips - One of the best experts on this subject based on the ideXlab platform.
-
incidence of infusion site reactions associated with peripheral Intravenous Administration of fosaprepitant
Supportive Care in Cancer, 2014Co-Authors: Jordan Lundberg, Brooke Sorgen Crawford, Gary Phillips, Michael J. Berger, Robert WesolowskiAbstract:Purpose Fosaprepitant is known to cause infusion-site reactions. However, there is limited data regarding these reactions including the effect of peripheral Intravenous Administration or other potential factors on their incidence. This single-institution retrospective study was undertaken to investigate the incidence of infusion-site reactions with single-dose Intravenous (IV) fosaprepitant when given through a peripheral line prior to Administration of chemotherapy. Risk factors for the development of infusion-site reactions with fosaprepitant were also explored.
Michael J. Berger - One of the best experts on this subject based on the ideXlab platform.
-
incidence of infusion site reactions associated with peripheral Intravenous Administration of fosaprepitant
Supportive Care in Cancer, 2014Co-Authors: Jordan Lundberg, Brooke Sorgen Crawford, Gary Phillips, Michael J. Berger, Robert WesolowskiAbstract:Purpose Fosaprepitant is known to cause infusion-site reactions. However, there is limited data regarding these reactions including the effect of peripheral Intravenous Administration or other potential factors on their incidence. This single-institution retrospective study was undertaken to investigate the incidence of infusion-site reactions with single-dose Intravenous (IV) fosaprepitant when given through a peripheral line prior to Administration of chemotherapy. Risk factors for the development of infusion-site reactions with fosaprepitant were also explored.
